anti-CD7 CAR-T cells / Institute of Hematology and Blood Diseases Hospital - LARVOL DELTA

CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P1 trial • Anemia • Aplastic Anemia • Hematological Disorders

GENE-EDITED UNIVERSAL CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOBLASTIC LYMPHOMA (EBMT 2024) - P2 | "A lymphodepletion regimen was administered using fludarabine (30 mg/m2 per day) and cyclophosphamide (500 mg/m2 per day) for three consecutive days (day -5 to day -3) before CAR-T infusion. UCD7-CAR T therapy is a safe and highly effective pediatric T-ALL/LBL treatment. But, more patients and longer follow-ups are needed for validation"

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • CNS Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • Transplantation • CD7

GENE-EDITED UNIVERSAL CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOBLASTIC LYMPHOMA (EBMT 2024) - P2 | "A lymphodepletion regimen was administered using fludarabine (30 mg/m2 per day) and cyclophosphamide (500 mg/m2 per day) for three consecutive days (day -5 to day -3) before CAR-T infusion. UCD7-CAR T therapy is a safe and highly effective pediatric T-ALL/LBL treatment. But, more patients and longer follow-ups are needed for validation"

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • CNS Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • Transplantation • CD7

CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Retrospective Study (ASH 2023) - P1, P2 | "Hence, given the comparable remission rate and remarkable safety, autologous CD7 CAR T-cell therapy would be prioritized for recommendation for r/r T-ALL/LBL patients with low tumor load and access to collect enough normal T cells from their own body for CAR T-cell manufacture. CD5 CAR T-cell therapy is regarded as an option for patients with CD5 positive encountering treatment failure or relapse after CD7 CAR T-cell therapy."

CAR T-Cell Therapy • Retrospective data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • CD5 • CD7 • IL6 • TNFA

Gene-Edited Universal CD7 Chimeric Antigen Receptor T Cells for Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (ASH 2023) - P2 | "A lymphodepletion regimen was administered to all patients using fludarabine (30 mg/m2 per day) and cyclophosphamide (500 mg/m2 per day) for three consecutive days (day -5 to day -3) before CAR-T infusion. UCD7-CAR T therapy is a safe and highly effective pediatric T-ALL/LBL treatment. More patients and longer follow-ups are needed for validation."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • CNS Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • Transplantation • CD7 • PI16

Universal anti-CD7 CAR-T cells targeting T-ALL and functional analysis of CD7 antigen on T/CAR-T cells. (PubMed, Hum Gene Ther) - "RNA-seq further confirmed an elevation of activated CD4 memory cell subpopulation. However, limited distinction on crucial regulatory genes and pathways was revealed, suggesting the safety and feasibility of UCAR-T application as well as the potential translational rather than transcriptional regulation of CD7 antigen."

CAR T-Cell Therapy • Journal • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD4 • CD7 • CD8

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies (clinicaltrials.gov) - P2 | N=22 | Recruiting | Sponsor: Ying Wang | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2023 ➔ Sep 2025 | Trial primary completion date: Sep 2022 ➔ Sep 2024

Enrollment open • Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Oncology • CD7

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. (PubMed, J Hematol Oncol) - "In this 2-year follow-up analysis, donor-derived CD7 CAR T-cell treatment demonstrated durable efficacy in a subset of patients with r/r T-ALL. Disease relapse was the main cause of treatment failure, and severe infection was a noteworthy late-onset adverse event."

CAR T-Cell Therapy • Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • CD7

Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r/r T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Interim Analysis from a Phase 2 Trial (ASH 2022) - P2 | "Interim results from a phase 2 trial of donor-derived CD7 CAR T cell therapy showed similar encouraging activity in treating r/r T-ALL with phase 1 trial. Relapse emerges as major issues impeding long-term outcomes. CD7-negative relapse was commonly observed under CAR T cell surveillance."

CAR T-Cell Therapy • Clinical • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Inflammation • Leukemia • Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • T Acute Lymphoblastic Leukemia • Transplantation • CD7

Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells (ASH 2022) - "In addition, CD7 knockout leads to elevation of CD4 memory cell population without impairing CAR-T cells function. Whether CD7 knockout will benefit the establishment of long-term memory is worth further evaluation."

CAR T-Cell Therapy • IO biomarker • Hematological Malignancies • Immune Modulation • Inflammation • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD2 • CD4 • CD5 • CD8 • TNFA

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies (clinicaltrials.gov) - P2 | N=22 | Not yet recruiting | Sponsor: Ying Wang

New P2 trial • Hematological Disorders • Hematological Malignancies • Oncology • CD7